Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients
Received 4 April 2018
Accepted for publication 1 June 2018
Published 6 September 2018 Volume 2018:14 Pages 2307—2312
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Prof. Dr. Roumen Kirov
Peer reviewer comments 2
Editor who approved publication: Dr Roger Pinder
Morgane Roulot,1,† Alessandra Minelli,2 Marco Bortolomasi,3 Elisabetta Maffioletti,2,4 Massimo Gennarelli,2,4 Marc Borsotto,1 Catherine Heurteaux,1 Jean Mazella1
1Molecular and Cellular Institute of Pharmacology, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275, Université Côte d’Azur, Valbonne, France; 2Department of Molecular and Translational Medicine, Biology and Genetic Division, University of Brescia, Brescia, Italy; 3Psychiatric Hospital “Villa Santa Chiara”, Verona, Italy; 4Genetic Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
†Morgane Roulot passed away on January 10, 2018
Purpose: Sortilin-derived propeptide (PE) and its synthetic analog spadin show strong antidepressant activity in rodents and, therefore, could be used as a biomarker to evaluate the clinical efficacy of antidepressant treatments. The aim of this study was to determine whether electroconvulsive therapy (ECT) modulates serum PE concentration in patients with treatment-resistant depression (TRD).
Patients and methods: Forty-five patients with major depressive disorder, who met the Diagnostic and Statistical Manual of Mental Disorders-IV criteria, were selected for this study.
Results: We did not observe any difference in the PE levels between TRD patients and controls (z=0.10, P=0.92), but we found a strong significant increase between the PE levels measured just before (T0) and about 1 month (T2) after ECT (z=-2.82, P=0.005). A significant difference between T0 and T2 was observed only in responders (z=-2.59, P=0.01), whereas no effect was found in nonresponders (z=-1.27, P=0.20). Interestingly, we found a significant correlation between the increase in PE levels and decrease in Montgomery -Åsberg Depression Rating Scale scores for the total patient sample (P=0.03).
Conclusion: This study indicates for the first time that ECT affects serum PE concentration in responders and, therefore, could contribute to the evaluation of the therapy success.
Keywords: sortilin propeptide, electroconvulsive therapy, treatment-resistant depressed patients, diagnosis
This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License. The full terms of the License are available at http://creativecommons.org/licenses/by/4.0/. The license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Download Article [PDF] View Full Text [HTML][Machine readable]